US FDA and Duke University to work together on cardiac safety research
This article was originally published in RAJ Devices
The US Food and Drug Administration and Duke University have signed a memorandum of understanding agreeing to collaborate on a number of projects focusing on cardiac safety research1.
You may also be interested in...
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.